Research Article
Volume 8 Issue 2 - 2021
Pharmacological Strategies to Manage COVID-19
Karine da Silva Guimarães1, Emilly Spnola de Moura Simão1, Giovano Lorenzi Agnolin1, Shirley Aparecida Machado de Camargo Agnolin1, Ana Paula Sobrinho Brito1, Mayara Peyroton Silva1, Wesley Pereira de Jesus Silva1, Felipe Luz Machado1, Ana Carolina Raeder La Cava Tinoco1, Beatriz Freitas Sales1, Eric Coelho Pedrosa de Freitas1, Jean Christian da Silva Aldayuz1 and Vanessa Estato1,2*
1Faculdade de Medicina, Universidade Estácio de Sá, Rio de Janeiro, RJ, Brazil
2Fundação Oswaldo Cruz, Laboratório de Imunofarmacologia, Rio de Janeiro, Brazil
*Corresponding Author: Vanessa Estato, Fundação Oswaldo Cruz, Laboratório de Imunofarmacologia, Rio de Janeiro, Brazil.
Received: November 18, 2020; Published: January 27, 2021




Abstract

COVID-19 is an infectious disease caused by SARS-CoV-2 that emerged in December 2019 in Wuhan, China. Great efforts have been made to find effective drugs to fight the virus. The aim of the study is to review the possibilities of pharmacological therapy in the management of COVID-19 and the repositioning of drugs, highlighting the main characteristics pointed out, advantages and limitations of the alternatives proposed by the scientific community. The study was descriptive, exploratory, cross-sectional, with a qualitative approach. Therapeutic strategies include antimalarials chloroquine and hydroxychloroquine; antibiotics azithromycin and association with chloroquine; antivirals lopinavir-ritonavir, ribavirin, remdesivir, favipiravir; glucocorticoids; immunoglobulins tocilizumab, sarilumab; convalescent plasma; antiparasitic ivermectin, emetine and anticoagulant heparin. Therapeutic possibilities are underway. However, these possibilities come up against the lack of studies proving their efficiency and effectiveness in large populations, given the recent emergence of the disease caused by SARSCoV-2.

Keywords: SARSCoV-2; COVID-19; Repositioning Drugs; Re

References

  1. Gao J., et al. “Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies”. Bioscience Trends1 (2020): 72-73.
  2. Maier HJ and Britton P. “Involvement of autophagy in coronavirus replication”. Viruses 4 (2012): 3440-3451.
  3. Coronavirus updates (2020).
  4. Ronald Dijkman and Lia van der Hoek. “Human Coronaviruses 229E and NL63: Close Yet Still So Far”. Journal of the Formosan Medical Association4 (2009): 270-279.
  5. Oosterhof L., et al. “Fatal lower respiratory tract disease with human corona virus NL63 in an adult haematopoietic cell transplant recipient”. Bone Marrow Transplant 45 (2010): 1115-1116.
  6. Susanna KP Lau., et al. “Molecular Epidemiology of Human Coronavirus OC43 Reveals Evolution of Different Genotypes over Time and Recent Emergence of a Novel Genotype due to”. Natural Recombination Journal of Virology 21 (2011): 11325-11337.
  7. Vabret Astrid., et al. “Detection of the New Human Coronavirus HKU1: A Report of 6 Cases”. NCBI: National Center for Biotechnology Information (2006).
  8. Tesini Brenda. “Coronavírus e Síndromes respiratórias agudas (COVID-19, MERS e SARS). MANUAL MSD: Versão Saúde para a Família (2020).
  9. “Sírio-Libanês. Previna-se contra o Novo Coronavírus” (2020).
  10. “Rede Bibliosus. Novo Coronavírus (Covid-19): informações básicas (2020).
  11. Verdecchia P., et al. “ACE-inibitori, sartani e sindrome respiratoria acuta da coronavirus 2 [ACE-inhibitors, angiotensin receptor blockers and severe acute respiratory syndrome caused by coronavirus]”. Giornale Italiano di Cardiologia 5 (2020): 321‐327.
  12. Zhang H., et al. “Enzima conversora de angiotensina 2 (ACE2) como um receptor SARS-CoV-2: mecanismos moleculares e potencial alvo terapêutico”. Cuidados Intensivos Med 46 (2020): 586-590.
  13. Wang Dawei., et al. “Características clínicas de 138 pacientes hospitalizados com nova pneumonia infectada por coronavírus 2019 em Wuhan, China”. JAMA Network (2020).
  14. Cascella M., et al. “Recursos, avaliação e tratamento do Coronavírus (COVID-19)”. In: StatPearls [Internet]. Ilha do Tesouro (FL): StatPearls Publishing (2020).
  15. Puja Mehta., et al. “COVID-19: consider cytokine storm syndromes and immunosuppression”. The lancet (2020).
  16. Lima Oliveira Amaral. “Claudio Márcio de. Informações sobre o novo coronavírus (COVID-19) (2020).
  17. report of the WHO-China Joint Mission on Coronavirus Disease 2019 (COVID-19) (2020).
  18. Araujo Castro de. Fernando Luis S. “Aspectos clínicos e terapêuticos da infecção da COVID-19 (2020).
  19. Ministério Da Saúde. “Boletim epidemiológico especial: COE-COVID19 (2020).
  20. Savarino A., et al. “Effects of Chloroquine on Viral Infections: An Old Drug Against Today's Diseases?” The Lancet Infectious Diseases (2003).
  21. Gautret Philippe., et al. “Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an openlabel non-randomized clinical trial”. International Journal Of Antimicrobial Agents (2020): 1-24.
  22. Mehra MR., et al. “Hydroxychloroquine or chloroquine with or without a macrolide for treatment of COVID-19: a multinational registry analysis”. The Lancet (2020).
  23. Katzung BG and Trevor AJ. “Farmacologia básica e clínica”. 13. edition. - Porto Alegre: AMGH (2017).
  24. Chu CM., et al. “Role of lopinavir/ritonavir in the treatment of SARS: initial virological and clinical findings”. Thorax 59 (2004): 252-256.
  25. Liu F., et al. “Patients of COVID-19 may benefit from sustained Lopinavir-combined regimen and the increase of Eosinophil may predict the outcome of COVID-19 progression”. International Journal of Infectious Diseases 95 (2020): 183‐191.
  26. Elfiky AA. “Anti-HCV, nucleotide inhibitors, repurposing against COVID-19”. Life Sciences (2020): 248.
  27. Khalili JS., et al. “Novel coronavirus treatment with ribavirin: Groundwork for an evaluation concerning COVID‐19”. Journal of Medical Virology (2020).
  28. Chu C., et al. “Role of lopinavir/ ritonavir in the treatment of SARS: initial virological and clinical findings”. Thorax (2004).
  29. Eastman RT., et al. “Remdesivir: A Review of Its Discovery and Development Leading to Human Clinical Trials for Treatment of COVID-19 (2020).
  30. Zhang L and Zhou R. “Mecanismo de Ligação do Remdesivir à RNA Polimerase Dependente do RNA SARS-CoV-2”. Preprints (2020).
  31. Aryal Sagar. “Remdesivir- Mecanismo de Ação, Usos, Síntese e COVID-19”. Microbiology Notes by Sagar Aryal (2018).
  32. Wang M., et al. “Remdesivir e a cloroquina inibem efetivamente o novo coronavírus recentemente emergido (2019-nCoV) In vitro”. Cell Research 30 (2020): 269-271.
  33. Furuta Youseke., et al. “Favipiravir (T-705), a broad spectrum inhibitor of viral RNA polymerase”. NCBI, National Center for Biotechnology Information (2017).
  34. Fabio Reis. “Favipiravir demonstra eficácia no tratamento do Coronavírus. Pfarma (2020).
  35. Pilkington Victoria., et al. “A review of the safety of favipiravir - a potential treatment in the COVID-19 pandemic?” NCBI, National Center for Biotechnology Information (2020).
  36. Wu C., et al. “Risk Factors Associated With Acute Respiratory Distress Syndrome and Death in Patients With Coronavirus Disease 2019 Pneumonia in Wuhan, China”. JAMA Internal Medicine (2020).
  37. Tang C., et al. “Caution against corticosteroid-based COVID-19 treatment”. The Lancet (2020).
  38. Scott Lesley J. “Tocilizumab: A Review in Rheumatoid Arthritis”. Drugs 17 (2017): 1865-1879.
  39. Chi Zhang., et al. “Cytokine release syndrome in severe COVID-19: interleukin-6 receptor antagonist tocilizumab may be the key to reduce mortality”. International Journal of Antimicrobial Agents5 (2020).
  40. Giambenedetto Simona Di., et al. “COVID‐19 group (Members are listed in the Acknowledgments section) - Off‐label Use of Tocilizumab in Patients with SARS‐CoV‐2”. Infection - Journal of Medical Virology (2020).
  41. JT Giles., et al. “Cardiovascular safety of tocilizumab versus etanercept in rheumatoid arthritis: a randomized controlled trial”. Arthritis and Rheumatology 72 (2020): 31-40.
  42. NEVES Ursula. Sarilumabe pode ser um aliado no combate ao novo coronavírus?” Pebmed. Rio de Janeiro (2020).
  43. Wang M., et al. “Remdesivir e a cloroquina inibem efetivamente o novo coronavírus recentemente emergido (2019-nCoV) In vitro”. Cell Research 30 (2020): 269-271.
  44. Wang Y., et al. “Unique epidemiological and clinical features of the emerging 2019 novel coronavirus pneumonia (COVID‐19) implicate special control measures”. Journal of Medical Virology (2020): 25748.
  45. REIS Fabio. “Sanofi e Regeneron testam medicamento para casos graves de coronavirus”. PFARMA. Rio de Janeiro (2020).
  46. Keith P., et al. “A novel treatment approach to the novel coronavirus: an argument for the use of therapeutic plasma exchange for fulminant COVID-19”. Critical Care 24 (2020): 128.
  47. Duan K., et al. “Effectiveness of convalescent plasma therapy in severe COVID-19 patients”. Proceedings of the National Academy of Sciences of the United States of America (2020).
  48. Dzik and Editor. “COVID-19 Convalescent Plasma: Now Is the Time for Better Science”. Transfusion Medicine Reviews (2020).
  49. Golan DE., et al. “Princípios de farmacologia: a base fisiopatológica da farmacoterapia. - 3 ed. Rio de Janeiro:Guanabara Koogan (2014).
  50. Gotz V., et al. “Os vírus da gripe A escapam da restrição MxA às custas da importação eficiente de RNP nuclear”. Scientific Reports 6 (2016): 23138.
  51. Lundberg L., et al. “Inibidores da importação e exportação nuclear alteram a distribuição de proteínas do capsídeo em células de mamíferos e reduzem a replicação do vírus da encefalite equina venezuelana”. Antiviral Research 3 (2013): 662-672.
  52. Tay Meu., et al. “Localização nuclear do vírus da dengue (DENV) 1-4 proteína não estrutural 5; proteção contra todos os 4 sorotipos de DENV pelo inibidor Ivermectina”. Antiviral Research 3 (2013): 301-306.
  53. Wagstaff KM., et al. “A ivermectina é um inibidor específico da importação nuclear mediada por importina alfa / beta, capaz de inibir a replicação do vírus HIV-1 e dengue”. A revista Bioquímica3 (2012): 851-856.
  54. Caly L. et al. “The FDA-approved Drug Ivermectin inhibits the replication of SARS-CoV-2 In vitro”. Antiviral Research (2020): 104787.
  55. Bleasel Martin D., et al. “Emetine, Ipecac, Ipecac Alkaloids and Analogues as Potential Antiviral Agents for Coronaviruses. Bleasel MD1, Peterson GM1)”. Pharmaceuticals 3 (2020). pii: E51.
  56. Tang N., et al. “Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy (2020).
  57. Hamerschlak Nelson., et al. “Utilização da Heparina e dos Anticoagulantes Orais na Prevenção e Tratamento da Trombose Venosa Profunda e da Embolia Pulmonar”. Arquivos Brasileiros de Cardiologia 3 (2020): 1996.
Citation: Vanessa Estato., et al. “Pharmacological Strategies to Manage COVID-19”. EC Cardiology 8.2 (2021): 06-24.

PubMed Indexed Article


EC Pharmacology and Toxicology
LC-UV-MS and MS/MS Characterize Glutathione Reactivity with Different Isomers (2,2' and 2,4' vs. 4,4') of Methylene Diphenyl-Diisocyanate.

PMID: 31143884 [PubMed]

PMCID: PMC6536005


EC Pharmacology and Toxicology
Alzheimer's Pathogenesis, Metal-Mediated Redox Stress, and Potential Nanotheranostics.

PMID: 31565701 [PubMed]

PMCID: PMC6764777


EC Neurology
Differences in Rate of Cognitive Decline and Caregiver Burden between Alzheimer's Disease and Vascular Dementia: a Retrospective Study.

PMID: 27747317 [PubMed]

PMCID: PMC5065347


EC Pharmacology and Toxicology
Will Blockchain Technology Transform Healthcare and Biomedical Sciences?

PMID: 31460519 [PubMed]

PMCID: PMC6711478


EC Pharmacology and Toxicology
Is it a Prime Time for AI-powered Virtual Drug Screening?

PMID: 30215059 [PubMed]

PMCID: PMC6133253


EC Psychology and Psychiatry
Analysis of Evidence for the Combination of Pro-dopamine Regulator (KB220PAM) and Naltrexone to Prevent Opioid Use Disorder Relapse.

PMID: 30417173 [PubMed]

PMCID: PMC6226033


EC Anaesthesia
Arrest Under Anesthesia - What was the Culprit? A Case Report.

PMID: 30264037 [PubMed]

PMCID: PMC6155992


EC Orthopaedics
Distraction Implantation. A New Technique in Total Joint Arthroplasty and Direct Skeletal Attachment.

PMID: 30198026 [PubMed]

PMCID: PMC6124505


EC Pulmonology and Respiratory Medicine
Prevalence and factors associated with self-reported chronic obstructive pulmonary disease among adults aged 40-79: the National Health and Nutrition Examination Survey (NHANES) 2007-2012.

PMID: 30294723 [PubMed]

PMCID: PMC6169793


EC Dental Science
Important Dental Fiber-Reinforced Composite Molding Compound Breakthroughs

PMID: 29285526 [PubMed]

PMCID: PMC5743211


EC Microbiology
Prevalence of Intestinal Parasites Among HIV Infected and HIV Uninfected Patients Treated at the 1o De Maio Health Centre in Maputo, Mozambique

PMID: 29911204 [PubMed]

PMCID: PMC5999047


EC Microbiology
Macrophages and the Viral Dissemination Super Highway

PMID: 26949751 [PubMed]

PMCID: PMC4774560


EC Microbiology
The Microbiome, Antibiotics, and Health of the Pediatric Population.

PMID: 27390782 [PubMed]

PMCID: PMC4933318


EC Microbiology
Reactive Oxygen Species in HIV Infection

PMID: 28580453 [PubMed]

PMCID: PMC5450819


EC Microbiology
A Review of the CD4 T Cell Contribution to Lung Infection, Inflammation and Repair with a Focus on Wheeze and Asthma in the Pediatric Population

PMID: 26280024 [PubMed]

PMCID: PMC4533840


EC Neurology
Identifying Key Symptoms Differentiating Myalgic Encephalomyelitis and Chronic Fatigue Syndrome from Multiple Sclerosis

PMID: 28066845 [PubMed]

PMCID: PMC5214344


EC Pharmacology and Toxicology
Paradigm Shift is the Normal State of Pharmacology

PMID: 28936490 [PubMed]

PMCID: PMC5604476


EC Neurology
Examining those Meeting IOM Criteria Versus IOM Plus Fibromyalgia

PMID: 28713879 [PubMed]

PMCID: PMC5510658


EC Neurology
Unilateral Frontosphenoid Craniosynostosis: Case Report and a Review of the Literature

PMID: 28133641 [PubMed]

PMCID: PMC5267489


EC Ophthalmology
OCT-Angiography for Non-Invasive Monitoring of Neuronal and Vascular Structure in Mouse Retina: Implication for Characterization of Retinal Neurovascular Coupling

PMID: 29333536 [PubMed]

PMCID: PMC5766278


EC Neurology
Longer Duration of Downslope Treadmill Walking Induces Depression of H-Reflexes Measured during Standing and Walking.

PMID: 31032493 [PubMed]

PMCID: PMC6483108


EC Microbiology
Onchocerciasis in Mozambique: An Unknown Condition for Health Professionals.

PMID: 30957099 [PubMed]

PMCID: PMC6448571


EC Nutrition
Food Insecurity among Households with and without Podoconiosis in East and West Gojjam, Ethiopia.

PMID: 30101228 [PubMed]

PMCID: PMC6086333


EC Ophthalmology
REVIEW. +2 to +3 D. Reading Glasses to Prevent Myopia.

PMID: 31080964 [PubMed]

PMCID: PMC6508883


EC Gynaecology
Biomechanical Mapping of the Female Pelvic Floor: Uterine Prolapse Versus Normal Conditions.

PMID: 31093608 [PubMed]

PMCID: PMC6513001


EC Dental Science
Fiber-Reinforced Composites: A Breakthrough in Practical Clinical Applications with Advanced Wear Resistance for Dental Materials.

PMID: 31552397 [PubMed]

PMCID: PMC6758937


EC Microbiology
Neurocysticercosis in Child Bearing Women: An Overlooked Condition in Mozambique and a Potentially Missed Diagnosis in Women Presenting with Eclampsia.

PMID: 31681909 [PubMed]

PMCID: PMC6824723


EC Microbiology
Molecular Detection of Leptospira spp. in Rodents Trapped in the Mozambique Island City, Nampula Province, Mozambique.

PMID: 31681910 [PubMed]

PMCID: PMC6824726


EC Neurology
Endoplasmic Reticulum-Mitochondrial Cross-Talk in Neurodegenerative and Eye Diseases.

PMID: 31528859 [PubMed]

PMCID: PMC6746603


EC Psychology and Psychiatry
Can Chronic Consumption of Caffeine by Increasing D2/D3 Receptors Offer Benefit to Carriers of the DRD2 A1 Allele in Cocaine Abuse?

PMID: 31276119 [PubMed]

PMCID: PMC6604646


EC Anaesthesia
Real Time Locating Systems and sustainability of Perioperative Efficiency of Anesthesiologists.

PMID: 31406965 [PubMed]

PMCID: PMC6690616


EC Pharmacology and Toxicology
A Pilot STEM Curriculum Designed to Teach High School Students Concepts in Biochemical Engineering and Pharmacology.

PMID: 31517314 [PubMed]

PMCID: PMC6741290


EC Pharmacology and Toxicology
Toxic Mechanisms Underlying Motor Activity Changes Induced by a Mixture of Lead, Arsenic and Manganese.

PMID: 31633124 [PubMed]

PMCID: PMC6800226


EC Neurology
Research Volunteers' Attitudes Toward Chronic Fatigue Syndrome and Myalgic Encephalomyelitis.

PMID: 29662969 [PubMed]

PMCID: PMC5898812


EC Pharmacology and Toxicology
Hyperbaric Oxygen Therapy for Alzheimer's Disease.

PMID: 30215058 [PubMed]

PMCID: PMC6133268


News and Events


April Issue Release

We always feel pleasure to share our updates with you all. Here, notifying you that we have successfully released the April issue of respective journals and the latest articles can be viewed on the current issue pages.

Submission Deadline for upcoming Issue

Ecronicon delightfully welcomes all the authors around the globe for effective collaboration with an article submission for the upcoming issue of respective journals. Submissions are accepted on/before May 04, 2021.

Certificate of Publication

Ecronicon honors with a "Publication Certificate" to the corresponding author by including the names of co-authors as a token of appreciation for publishing the work with our respective journals.

Best Article of the Issue

Editors of respective journals will always be very much interested in electing one Best Article after each issue release. The authors of the selected article will be honored with a "Best Article of the Issue" certificate.

Certifying for Review

Ecronicon certifies the Editors for their first review done towards the assigned article of the respective journals.

Latest Articles

The latest articles will be updated immediately on the articles in press page of the respective journals.

Immediate Assistance

The prime motto of this team is to clarify all the queries without any delay or hesitation to avoid the inconvenience. For immediate assistance on your queries please don't hesitate to drop an email to editor@ecronicon.uk